PMID- 33611973
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20220209
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 28
IP  - 2
DP  - 2022 Mar
TI  - Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical 
      and economic outcomes in patients treated with pomalidomide or daratumumab.
PG  - 395-409
LID - 10.1177/1078155221995532 [doi]
AB  - INTRODUCTION: Real-world evidence on later line treatment of relapsed/refractory 
      multiple myeloma (RRMM) is sparse. We evaluated clinical outcomes among RRMM 
      patients in the 1-year following treatment with pomalidomide or daratumumab and 
      compared economic outcomes between RRMM patients and non-MM patients. PATIENT AND 
      METHODS: Adult patients with >/=1 claim of pomalidomide or daratumumab were 
      identified between January 2012 and February 2018 using IQVIA PharMetrics(R) Plus 
      US claims database. Patients were required to have a diagnosis or treatment for 
      MM and a claim of any immunomodulatory drugs and proteasome inhibitors before the 
      index date. Mean time to new therapy, overall survival (OS) using Kaplan-Meier 
      curve and adverse events (AEs) were reported over the 1-year post-index period. 
      RRMM patients were also matched to a non-MM comparator cohort and economic 
      outcomes were compared between the two cohorts. RESULTS: 289 RRMM patients were 
      matched to 1,445 patients without MM. Most prevalent hematological AE was anemia 
      (72.0%) and non-hematological AE was infections (75.4%). Mean (SD) time to a new 
      treatment was 4.7 (5.3) months and median OS was 14.6 months. RRMM patients had 
      significantly higher hospitalizations and physician office visits (Both 
      P < .0001) compared to non-MM patients. Adjusting for baseline characteristics, 
      patients with RRMM had 4.9 times (95% CI 3.8-6.4, P < .0001) the total healthcare 
      costs compared with patients without MM. The major driver of total costs among 
      RRMM patients was pharmacy costs (67.3%). CONCLUSION: RRMM patients showed a high 
      frequency of AEs, low OS, and a substantial economic burden suggesting need for 
      effective treatment options.
FAU - Richter, Joshua
AU  - Richter J
AUID- ORCID: 0000-0002-0274-0585
AD  - Tisch Cancer institute at Mount Sinai Medical Center, New York, NY, USA.
FAU - Anupindi, Vamshi Ruthwik
AU  - Anupindi VR
AD  - IQVIA, Falls Church, VA, USA.
FAU - Yeaw, Jason
AU  - Yeaw J
AD  - IQVIA, Falls Church, VA, USA.
FAU - Kudaravalli, Suneel
AU  - Kudaravalli S
AD  - Oncopeptides Inc, Waltham, MA, USA.
FAU - Zavisic, Stojan
AU  - Zavisic S
AD  - Oncopeptides AB, Stockholm, Sweden.
FAU - Shah, Drishti
AU  - Shah D
AD  - IQVIA, Falls Church, VA, USA.
LA  - eng
PT  - Journal Article
DEP - 20210220
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - 0 (Antibodies, Monoclonal)
RN  - 4Z63YK6E0E (daratumumab)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - D2UX06XLB5 (pomalidomide)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Dexamethasone/therapeutic use
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Thalidomide/analogs & derivatives
OTO - NOTNLM
OT  - Myeloma
OT  - chemotherapy
OT  - daratumumab
OT  - pomalidomide
OT  - real-world
EDAT- 2021/02/23 06:00
MHDA- 2022/02/10 06:00
CRDT- 2021/02/22 05:42
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2021/02/22 05:42 [entrez]
AID - 10.1177/1078155221995532 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2022 Mar;28(2):395-409. doi: 10.1177/1078155221995532. Epub 
      2021 Feb 20.